Literature DB >> 16224628

Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003.

Carlos Kiffer1, Andre Hsiung, Carmen Oplustil, Jorge Sampaio, Elsa Sakagami, Philip Turner, Caio Mendes.   

Abstract

Establish the susceptibility pattern of Gram-negative bacteria causing infections in ICU patients, MYSTIC Program Brazil 2003. Gram-negative bacteria (n = 1,550) causing nosocomial infections were collected at 20 Brazilian centers. The central laboratory confirmed the identification and performed the susceptibility tests by Etest methodology (AB Biodisk, Solna, Sweden) for meropenem, imipenem, ciprofloxacin, ceftazidime, cefepime, cefotaxime, piperacillin/tazobactam, gentamicin, and tobramycin. Interpretation criteria used were according to National Committee for Clinical Laboratory Standards (NCCLS). Pseudomonas aeruginosa (30.3%) was the most frequent isolate, followed by E. coli (18.6%), Klebsiella pneumoniae (16.9%), Acitenobacter baumannii (8.8%), and Enterobacter cloacae (7.1%). Pseudomonas aeruginosa (n=470) isolates presented susceptibility rates of 64% to meropenem, 63.8% to piperacillin/tazobactam, 63.4% to amikacin, 58.7% to imipenem. Acitenobacter baumannii presented susceptibility rates to meropenem of 97.1%, and 73% to tobramycin. E. coli and K. pneumoniae were highly susceptible to both carbapenems. Carbapenem resistance among the Enterobacteriaceae is still rare in the region. Acitenobacter baumannii and P. aeruginosa presented elevated resistance rates to all antimicrobials. Since they play an important role in nosocomial infections in this environment, the use of empirical combination therapy to treat these pathogens may be justified.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16224628     DOI: 10.1590/s1413-86702005000300004

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  7 in total

1.  High prevalence of metallo-beta-lactamase and 16S rRNA methylase coproduction among imipenem-resistant Pseudomonas aeruginosa isolates in Brazil.

Authors:  Yohei Doi; Angela C R Ghilardi; Jennifer Adams; Doroti de Oliveira Garcia; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

2.  Carbapenem-resistant Pseudomonas aeruginosa: association with virulence genes and biofilm formation.

Authors:  Iara Rossi Gonçalves; Raquel Cristina Cavalcanti Dantas; Melina Lorraine Ferreira; Deivid William da Fonseca Batistão; Paulo Pinto Gontijo-Filho; Rosineide Marques Ribas
Journal:  Braz J Microbiol       Date:  2016-11-26       Impact factor: 2.476

3.  Characterization of class 1 integrons and antibiotic resistance genes in multidrug-resistant Salmonella enterica isolates from foodstuff and related sources.

Authors:  Vinicius B Ribeiro; Nilton Lincopan; Mariza Landgraf; Bernadete D G M Franco; Maria T Destro
Journal:  Braz J Microbiol       Date:  2011-06-01       Impact factor: 2.476

4.  Carbapenem-resistant Acinetobacter baumannii outbreak at university hospital.

Authors:  E H Takagi; N Lincopan; V C Cassettari; L F Passadore; E M Mamizuka; M B Martinez
Journal:  Braz J Microbiol       Date:  2009-06-01       Impact factor: 2.476

5.  Antibacterial effect of silver nanoparticles in Pseudomonas aeruginosa.

Authors:  R Salomoni; P Léo; A F Montemor; B G Rinaldi; Mfa Rodrigues
Journal:  Nanotechnol Sci Appl       Date:  2017-06-29

6.  Is nosocomial Escherichia coli bacteremia a predictive risk factor for mortality?

Authors:  Felipe F Tuon; Jaime L Rocha; Fernanda A Guadagnin; Márcia S Alves
Journal:  Braz J Infect Dis       Date:  2013-09-20       Impact factor: 3.257

7.  Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.

Authors:  Felipe Francisco Tuon; Juliette Cieslinski; Suellen da Silva Rodrigues; Fernando Brandão Serra; Marina Della-Negra de Paula
Journal:  Braz J Infect Dis       Date:  2020-04-28       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.